Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes the MIRACL study: A randomized controlled trial

Journal of the American Medical Association

Volumn 285, Issue 13, 2001, Pages 1711-1718

  Schwartz, G G ^a   Olsson, A G ^a   Ezekowitz, M D ^a   Ganz, P ^a   Oliver, M F ^a   Waters, D ^a   Zeiher, A ^a   Chaitman, B R ^a   Leslie, S ^a   Stern, T ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; PLACEBO;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; EXPERIENCE; FEMALE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS;

AGED; ANGINA, UNSTABLE; ANTICHOLESTEREMIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; PYRROLES; RECURRENCE; SURVIVAL ANALYSIS;

EID: 0035804846     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1062-1458(01)00368-3     Document Type: Article

References (19)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
4. Inhibition of the platelet glycoprotein llb/llla receptor with tirofiban in unstable angina and non-Q wave myocardial infarction
5. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study
6. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month
7. Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reserve
8. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: The RECIFE (Reduction of Cholesterol in Ischemia and Function of Endothelium) Trial
9. Hyperlipidemia and coronary disease: Correction of the increased thrombogenic potential with cholesterol reduction
10. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type lla hypercholesterolemia
11. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis
12. Long-term effects of pravastatin on plasma concentration of C-reactive protein
13. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction
14. NOVACODE serial ECG classification system for clinical trials and epidemiologic studies
15. Regression models and life tables
16. Evaluation of survival data and two new rank order statistics arising in its consideration
17. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
18. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the Post Coronary Artery Bypass Graft Trial